Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx is a clinical-stage biopharmaceutical company with a promising lead drug candidate and a strong financial position, with $12 million in cash and no debt. The company's recent milestones include a new CFO appointment, positive results from interim analyses of their ongoing Phase III TIGeR-PaC trial, and strong revenue growth for its commercial product RenovoCath. Based on these positive developments and the potential for a billion dollar market, the analyst believes there is significant upside potential for RenovoRx's stock.

Bears say

RenovoRx is a clinical-stage biopharmaceutical company that has a negative outlook, as their particular drug delivery platform has faced slow growth due to a long induction phase and a high percentage of ineligible patients for randomization. Additionally, the company's valuation is not attractive, and they have reported losses on issuances of financial instruments. It is important to note that while RenovoRx has made progress in clinical development and commercialization, it may not be enough to offset the challenges faced by their current approach.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Jul 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.